|
US4166452A
(en)
|
1976-05-03 |
1979-09-04 |
Generales Constantine D J Jr |
Apparatus for testing human responses to stimuli
|
|
US4256108A
(en)
|
1977-04-07 |
1981-03-17 |
Alza Corporation |
Microporous-semipermeable laminated osmotic system
|
|
US4265874A
(en)
|
1980-04-25 |
1981-05-05 |
Alza Corporation |
Method of delivering drug with aid of effervescent activity generated in environment of use
|
|
LU86084A1
(fr)
|
1985-09-20 |
1987-04-02 |
Faco Sa |
Apparei de massage electrique
|
|
US5102417A
(en)
|
1985-11-07 |
1992-04-07 |
Expandable Grafts Partnership |
Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft
|
|
US4800882A
(en)
|
1987-03-13 |
1989-01-31 |
Cook Incorporated |
Endovascular stent and delivery system
|
|
US4886062A
(en)
|
1987-10-19 |
1989-12-12 |
Medtronic, Inc. |
Intravascular radially expandable stent and method of implant
|
|
WO1990013332A1
(en)
|
1989-05-11 |
1990-11-15 |
Cedars-Sinai Medical Center |
Stent with sustained drug delivery
|
|
EP0470246B1
(en)
|
1990-02-28 |
1995-06-28 |
Medtronic, Inc. |
Intralumenal drug eluting prosthesis
|
|
US5419760A
(en)
|
1993-01-08 |
1995-05-30 |
Pdt Systems, Inc. |
Medicament dispensing stent for prevention of restenosis of a blood vessel
|
|
US5429634A
(en)
|
1993-09-09 |
1995-07-04 |
Pdt Systems |
Biogenic implant for drug delivery and method
|
|
US6774278B1
(en)
|
1995-06-07 |
2004-08-10 |
Cook Incorporated |
Coated implantable medical device
|
|
US5833651A
(en)
|
1996-11-08 |
1998-11-10 |
Medtronic, Inc. |
Therapeutic intraluminal stents
|
|
US6166050A
(en)
|
1998-12-14 |
2000-12-26 |
American Home Products Corporation |
3,4-diamino-3-cyclobutene-1,2-dione derivatives which inhibit leukocyte adhesion mediated by VLA-4
|
|
US6294192B1
(en)
|
1999-02-26 |
2001-09-25 |
Lipocine, Inc. |
Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
|
|
AR033803A1
(es)
|
2000-03-01 |
2004-01-07 |
Smithkline Beecham Corp |
Compuestos de dianilino escuarano, composiciones farmaceuticas que los comprenden, y el uso de los mismos en la fabricacion de medicamentos para tratar enfermedades mediadas por quimioquinas
|
|
WO2001092202A1
(en)
|
2000-05-30 |
2001-12-06 |
Smithkline Beecham Corporation |
Il-8 receptor antagonists
|
|
DE60230722D1
(de)
|
2001-01-16 |
2009-02-26 |
Smithkline Beecham Corp |
Il-8-rezeptor-antagonisten
|
|
US20040048897A1
(en)
|
2001-01-16 |
2004-03-11 |
Mccleland Brent |
Il-8 receptor antagonists
|
|
US20030204085A1
(en)
|
2001-02-02 |
2003-10-30 |
Taveras Arthur G. |
3, 4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor antagonists
|
|
EP1355875A1
(en)
|
2001-02-02 |
2003-10-29 |
Schering Corporation |
3,4-di-substituted cyclobutene-1, 2-diones as cxc chemokine receptor antagonists
|
|
US20040106794A1
(en)
|
2001-04-16 |
2004-06-03 |
Schering Corporation |
3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
|
|
US20040097547A1
(en)
|
2001-04-16 |
2004-05-20 |
Taveras Arthur G. |
3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
|
|
US7132445B2
(en)
|
2001-04-16 |
2006-11-07 |
Schering Corporation |
3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
|
|
KR20100008794A
(ko)
|
2001-04-16 |
2010-01-26 |
쉐링 코포레이션 |
Cxc-케모카인 수용체 리간드로서의 3,4-이치환된 사이클로부텐-1,2-디온
|
|
NZ535314A
(en)
|
2002-03-18 |
2007-08-31 |
Schering Corp |
Combination treatments for chemokine-mediated diseases
|
|
US6770729B2
(en)
|
2002-09-30 |
2004-08-03 |
Medtronic Minimed, Inc. |
Polymer compositions containing bioactive agents and methods for their use
|
|
DE602004025458D1
(de)
|
2003-04-18 |
2010-03-25 |
Schering Corp |
SYNTHESE VON 2-HYDROXY-N,N-DIMETHYL-3-ii2-i1(R)-(5-METHYL-2-FURANYL)PROPYL AMINO -3,4-DIOXO-1-CYCLOBUTEN-1-YL AMINO BENZAMID
|
|
CN1914187B
(zh)
|
2004-01-30 |
2012-01-25 |
先灵公司 |
Cxc趋化因子受体配位体的结晶多晶型物
|
|
US7521457B2
(en)
|
2004-08-20 |
2009-04-21 |
Boehringer Ingelheim International Gmbh |
Pyrimidines as PLK inhibitors
|
|
GB0419481D0
(en)
|
2004-09-02 |
2004-10-06 |
Cancer Rec Tech Ltd |
Isoindolin-1-one derivatives
|
|
DE102005035742A1
(de)
|
2005-07-29 |
2007-02-01 |
Merck Patent Gmbh |
Quadratsäurederivate II
|
|
JP2009542700A
(ja)
|
2006-07-07 |
2009-12-03 |
シェーリング コーポレイション |
Cxcケモカイン受容体リガンドとしての3,4−ジ置換シクロブテン−1,2−ジオン
|
|
AU2008223348A1
(en)
|
2007-03-07 |
2008-09-12 |
Alantos Pharmaceuticals Holding, Inc. |
Metalloprotease inhibitors containing a heterocyclic moiety
|
|
MX2009013276A
(es)
|
2007-06-06 |
2010-01-25 |
Novartis Ag |
Compuestos anti-inflamatorios de ciclobutenodiona sustituida.
|
|
EP2178826B1
(en)
|
2007-07-03 |
2017-05-17 |
Merck Sharp & Dohme Corp. |
Process and intermediates for the synthesis of 1,2-substituted 3,4-dioxo-1-cyclobutene compounds
|
|
US20100249439A1
(en)
|
2007-07-05 |
2010-09-30 |
Vincenzo Liotta |
Process for controlled crystal size in 1,2-substituted 3,4-dioxo-1-cyclobutene compounds
|
|
WO2009012375A2
(en)
|
2007-07-19 |
2009-01-22 |
Wyeth |
Squarate kinase inhibitors
|
|
CA2700841A1
(en)
|
2007-09-27 |
2009-04-02 |
The United States Of America, As Represented By The Secretary, Departmen T Of Health And Human Services |
Isoindoline compounds for the treatment of spinal muscular atrophy and other uses
|
|
EP2252327A2
(en)
|
2007-12-04 |
2010-11-24 |
Schering Corporation |
Methods of treating copd
|
|
MX2010014310A
(es)
|
2008-06-24 |
2011-02-15 |
Topotarget As |
Derivados de acido escuarico como inhibidores de la nicotinamida.
|
|
UA103198C2
(en)
|
2008-08-04 |
2013-09-25 |
Новартис Аг |
Squaramide derivatives as cxcr2 antagonists
|
|
EP2350067A2
(en)
|
2008-10-16 |
2011-08-03 |
Schering Corporation |
Pyrrolidine, piperidine and piperazine derivatives and methods of use thereof
|
|
WO2010063802A1
(en)
|
2008-12-05 |
2010-06-10 |
Novartis Ag |
3, 4-di-substituted cyclobutene- 1, 2 -diones as cxcr2 receptor antagonists
|
|
WO2010091543A1
(en)
|
2009-02-10 |
2010-08-19 |
Merck Sharp & Dohme Corp. |
Novel hydrazino-cyclobut-3-ene-1, 2-dione derivatives as cxcr2 antagonists
|
|
WO2010131145A1
(en)
|
2009-05-12 |
2010-11-18 |
Pfizer Limited |
Cyclobutenedione derivatives
|
|
FR2961695B1
(fr)
|
2010-06-29 |
2012-07-06 |
Galderma Res & Dev |
Utilisation de composes dans le traitement ou la prevention de troubles cutanes
|
|
US8648118B2
(en)
|
2010-12-17 |
2014-02-11 |
Boehringer Ingelheim International Gmbh |
Bicyclic ring system substituted amide functionalised phenols as medicaments
|
|
US8648070B2
(en)
|
2010-12-17 |
2014-02-11 |
Boehringer Ingelheim International Gmbh |
Bicyclic ring system substituted sulfonamide functionalised phenols as medicaments
|
|
WO2013030803A1
(en)
|
2011-09-02 |
2013-03-07 |
Novartis Ag |
Choline salt of an anti - inflammatory substituted cyclobutenedione compound
|
|
FR2981935B1
(fr)
|
2011-10-28 |
2015-08-07 |
Galderma Res & Dev |
Nouveaux composes di-substitues de la diamino-3,4-cyclobutene-3-dione-1,2 utiles dans le traitement de pathologies mediees par des chimiokines.
|
|
FR2981936B1
(fr)
|
2011-10-28 |
2013-12-20 |
Galderma Res & Dev |
Nouveaux composes di-substitues de la diamino-3,4-cyclobutene-3-dione-1,2 utiles dans le traitement de pathologies mediees par des chimiokines.
|
|
FR2981934B1
(fr)
*
|
2011-10-28 |
2013-12-20 |
Galderma Res & Dev |
Nouveaux composes di-substitues de la diamino-3,4-cyclobutene-3-dione-1,2 utiles dans le traitement de pathologies mediees par des chimiokines.
|
|
SI2780373T1
(sl)
*
|
2011-11-16 |
2019-12-31 |
Boehringer Ingelheim International Gmbh |
Protitelesa proti IL-36R
|
|
CA2873984A1
(en)
|
2012-05-23 |
2013-11-28 |
Stemergie Biotechnology Sa |
Inhibitors of the activity of complex (iii) of the mitochondrial electron transport chain and use thereof
|
|
WO2015170430A1
(ja)
|
2014-05-08 |
2015-11-12 |
学校法人慶應義塾 |
大動脈解離後の炎症性障害抑制剤
|
|
EP3220951A1
(en)
|
2014-11-17 |
2017-09-27 |
MedImmune Limited |
Therapeutic combinations and methods for treating neoplasia
|
|
TWI734715B
(zh)
|
2015-11-19 |
2021-08-01 |
美商卡默森屈有限公司 |
趨化因子受體調節劑
|
|
TWI724056B
(zh)
*
|
2015-11-19 |
2021-04-11 |
美商卡默森屈有限公司 |
Cxcr2抑制劑
|
|
ES3067325T3
(en)
|
2018-01-08 |
2026-05-21 |
Chemocentryx Inc |
Methods of treating generalized pustular psoriasis with an antagonist of ccr6 or cxcr2
|